

Claims

1. An isolated, substantially purified nucleotide sequence chosen from the group comprising SEQ. ID. NO. 1 - 12 and homologues thereof.
2. A nucleotide sequence which is complementary to the sequence according to claim 1.
- 5 3. A nucleotide sequence which hybridises under stringent conditions to a sequence according to claim 1.
4. A nucleotide sequence according to claim 1, wherein the homology is at least 70, 80, 90, 95 or 98 %.
5. An isolated, substantially pure nucleotide sequence induced in differentiated mammalian cells by the addition of a thiazolidinedione, such as pioglitazone, **characterized** in that said sequence is homologous to a sequence chosen among SEQ. ID. NO. 1 - 12.
- 10 6. A nucleotide sequence according to claim 5, **characterized** in that the differentiated mammalian cells are adipocytes.
7. A method for evaluating substances for insulin regulating properties *in vitro* in a culture of mammalian cells, **characterized** in that a sequence according to claim 1 is used as a
15 marker for insulin regulating action.
8. Method for evaluating substances for insulin regulating properties *in vitro* in a culture of mammalian cells, **characterized** in that a transcript according to claim 5 is used as a marker for insulin regulating action
- 20 9. Method according to claim 7, **characterized** in that adipocytes are used as model cells.
10. Method according to claim 8, **characterized** in that adipocytes are used as model cells.
11. Method according to claim 7, **characterized** in that hepatic cells are used as model cells.
12. Method according to claim 8, **characterized** in that hepatic cells are used as model cells
- 25 13. Method according to claim 7, **characterized** in that muscle tissue cells are used as model cells.

09875945.060907

14. Method according to claim 8, **characterized** in that muscle tissue cells are used as model cells.
15. Method according to claim 7, **characterized** in that pancreatic cells are used as model cells.
- 5 16. Method according to claim 8, **characterized** in that pancreatic cells are used as model cells.
17. A substance identified as having insulin regulating properties using the method according to any one of claims 7 - 16.
- 10 18. Use of a sequence according to claim 1, or information derived therefrom, for the manufacture of a medicament.
19. Use of a sequence according to claim 1, or information derived therefrom, for the manufacture of a veterinary preparation.
20. Use of a sequence according to claim 1, or information derived therefrom, for the manufacture of a medicament for the treatment of diabetes.
- 15 21. Use of a sequence according to claim 1, or information derived therefrom, for the manufacture of a medicament for the treatment of obesitas.
22. Use of a sequence according to claim 5, or information derived therefrom, for the manufacture of a medicament.
- 20 23. Use of a sequence according to claim 5, or information derived therefrom, for the manufacture of a veterinary preparation.
24. Use of a sequence according to claim 5, or information derived therefrom, for the manufacture of a medicament for the treatment of diabetes.
25. Use of a sequence according to claim 5, or information derived therefrom, for the manufacture of a medicament for the treatment of obesitas.
- 25 26. Use of a substance according to claim 17, for the manufacture of a medicament.
27. Use of a substance according to claim 17, for the manufacture of a veterinary preparation.

00075945.060801

28. Use of a substance according to claim 17, for the manufacture of a medicament for the treatment of diabetes.

29. Use of a substance according to claim 17, for the manufacture of a medicament for the treatment of obesitas.

5 30. A pharmaceutical composition, comprising a substance according to claim 17 in a pharmaceutically effective amount.

31. A veterinary preparation, comprising a substance according to claim 17 in an physiologically effective amount.

10 32. An assay for the screening of substances in respect of their insulin regulating properties, **characterized** in that a sequence according to claim 1 or 5 is used as marker for insulin regulating properties.

33. A substance having insulin regulating properties, identified using an assay according to claim 32.

15 34. An assay for the diagnosis of IRS-2 related metabolic disorders and/or differentiating between various types or stages of the disorder, **characterized** in that a sequence according to claim 1 or information derived therefrom is used in said assay.

35. An assay for the diagnosis of diabetes and/or differentiating between various types or stages of the disease, **characterized** in that a sequence according to claim 1 or information derived therefrom is used in said assay.

20 36. A method for determining if a patient in need of treatment with an insulin regulating substance has the predisposition to respond to the treatment, **characterized** in that the activation of IRS-2 is measured, e.g. by determining the amount or relative increase/decrease of the IRS-2 protein, or the corresponding mRNA when administering the insulin regulating substance in question to a sample of cells taken from the patient.

25 37. A method for determining if a patient in need of treatment with an insulin regulating, e.g. insulin regulating substance has the predisposition to respond to the treatment, wherein at least one sequence chosen among SEQ.ID.NO. 1 - 12 is used as a marker when

09875945-060001

administering the insulin regulating substance in question to a sample of cells taken from the patient.

38. A method according to claim 36 or 37, characterized in that the cells taken from the patient are chosen among blood cells, adipocyte cells, muscle cells, and liver cells.

5 39. A method according to claim 36 or 37, characterized in that the cells are blood cells.

00875945 060801
108090 5452860